TYENNE 162 MG/0.9 ML AUTOINJCT
FDA nonproprietary name: tocilizumab-aazg
For 0.9 mL
Pharmacies pay
$738.90 filed
0.9 × $820.99658 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$716.49 filed
0.9 × $796.1023 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.97× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Tyenne*” / “Tocilizumab-Aazg” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$854.74 estimated
$738.90 + $110.84 (15%) + $5.00 fee per fill = $854.74
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
TYENNE 162 MG/0.9 ML AUTOINJCT is how the CMS NADAC file names this product. The FDA NDC Directory lists it as tocilizumab-aazg, under the trade name “TYENNE”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is Fresenius Kabi USA, LLC.
FDA’s Established Pharmacologic Class for it is Interleukin-6 Receptor Antagonist.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).
NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $738.90 for 0.9 mL (0.9 × $820.99658 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
All 2 NDCs
- 65219-0584-01 · Fresenius Kabi USA, LLC · $820.99658 per ML · eff. 2026-09-23 filed
- 65219-0596-01 · Fresenius Kabi USA, LLC · $820.99658 per ML · eff. 2026-09-23 filed
Compared with its class
The middle of its 2 NDCs’ NADAC prices is $820.99658 per ML filed.
Of the 3 other products in FDA’s Interleukin-6 Receptor Antagonist class priced per ML, 3 have a higher middle NADAC price and 0 a lower one. The one in the middle is KEVZARA 200 MG/1.14 ML SYRINGE, at $2,068.06403 per ML filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $716.49 for 0.9 mL, at an average of $796.1023 per ML in 2024 (2024-01-01 to 2024-12-31) for “Tyenne*” and “Tocilizumab-Aazg”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 494 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 0.9 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 0.9 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for TYENNE 162 MG/0.9 ML AUTOINJCT labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Tyenne* / Tocilizumab-Aazg: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name. *: CMS says this average reflects multiple routes of administration, which may have different unit prices. All 2 NADAC NDCs the name join matched to it have an FDA route including SUBCUTANEOUS.
- Why does this page start at 0.9 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 0.9 mL in one package for all 2 NDCs of this product (“1 SYRINGE, GLASS in 1 CARTON (65219-584-01) / .9 mL in 1 SYRINGE, GLASS”), so the card starts at one package: 0.9 ML. Change it to match your prescription.